Ben Cravatt

Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals) and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award. He also holds memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in biological sciences and a B.A. in history. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996 and joined the faculty at TSRI in 1997.